Each month, the Biosimilars Council sends a newsletter with the latest updates in the biosimilars industry including policy movement, educational resources and upcoming events. To stay current on biosimilars, sign-up to receive these monthly updates on the form to the right.
Biosimilars Bulletin | June 2020
News and Updates
Matrix Global Advisors Report Reveals Key Lessons for the United States from Europe’s Biosimilar Experience
A new report from Matrix Global Advisors (MGA) details “lessons learned” from the European biosimilars experience that can improve access to these medicines for America’s patients.
Biosimilars of Humira Have Saved Europe a Bundle, JAMA Reports
Biosimilar versions of the antibody product adalimumab have taken some of Humira’s market in Europe and other countries, dropping AbbVie’s foreign sales of Humira by 27 percent last year.
ASCO Models Show Biosimilar Pegfilgrastim Savings Aid More Patients
Switching patients with cancer to biosimilar pegfilgrastim for prophylaxis treatment of chemotherapy-induced febrile neutropenia could generate significant savings for adjuvant treatment, investigators found in studies presented at ASCO20 Virtual, the annual meeting of the American Society of Clinical Oncology (ASCO).
Studies Reveal Switch to Bevacizumab, Rituximab Biosimilars Yields Millions in Savings
Cost savings are likely to occur should payers switch from originator bevacizumab or rituximab to their respective biosimilars, according to research from two studies presented at the Virtual 2020 International Society for Pharmacoeconomics and Outcomes Research meeting
10 Years of Biosimilars: Lessons and Trends
The U.S. regulatory and litigation pathway for biosimilars was signed into law in March 2010. This article explores lessons learned from the last ten years and trends moving forward.
A Chat on Biosimilars With Sandoz’s U.S. President Carol Lynch
Life Science Leader spoke with Sandoz U.S. President Carol Lynch at the New York Marriott Marquis during the 2020 BIO CEO & Investor Conference to learn more about the future of biosimilars.
Shared Savings Demonstration for Biosimilars in Medicare: An Opportunity to Promote Biologic Drug Competition
Biosimilars have the potential to reduce health care spending and promote competition. A new white paper by Matrix Global Advisors shows how a shared savings model can promote biosimilar adoption and reduce Medicare Part B spending.
Part 1: Christine Simmon Discusses the Individual Mandate and Biosimilars
Executive Director Christine Simmon discusses potential legislation that AAM is advocating for and how the upcoming election and Supreme Court decision will affect biosimilars.
Part 2: Christine Simmon Discusses Payer Influence on Provider Behavior
Executive Director Christine Simmon discusses the new pathway for insulin biosimilars and the struggles between payers and providers over biosimilar choice.
New Resource: Lessons for the United States on Europe’s Biosimilar Experience
A decade after the United States established its own biosimilars pathway, this new white paper discusses that we are past time to move beyond this outdated perception and consider what the United States can learn from Europe’s experience with biosimilars.
New Resource: Biosimilars Approvals and Launches
A comprehensive resource on the latest FDA-approved biosimilars, including launch dates where applicable.
Increase Patient Access to Lower-Cost Biosimilar Medicines
The three legislative proposals outlined in this one-pager would help strengthen biosimilar adoption and each is designed to ensure savings for patients and Medicare.
Planning + Ready Join us November 9-11, 2020 in North Bethesda, Maryland for GRx+Biosims 2020. GRx+Biosims is the premier scientific and regulatory event for the U.S. generics and biosimilars industries, featuring timely programming relevant to technical, regulatory and policy professionals. Hear from top-in-their-field officials and subject-matter experts; share knowledge and best practices; and gain insights on navigating the regulatory process approvals and the evolving policy landscape.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available on our about page.
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 23 percent of total drug spending. Additional information is available at www.accessiblemeds.org.